The proteinuria—hypertriglyceridemia connection as a basis for novel therapeutics for nephrotic syndrome

• Published in: Translational research : the journal of laboratory and clinical medicine 2015-04, Vol.165 (4), p.499-504
• Main Authors: Clement, Lionel C, Macé, Camille, Del Nogal Avila, Maria, Marshall, Caroline B, Chugh, Sumant S
• Format: Article
• Language: English
• Subjects: Angiopoietin-Like Protein 4; Angiopoietins - genetics; Angiopoietins - pharmacology; Humans; Hypertriglyceridemia - complications; Internal Medicine; Nephrotic Syndrome - drug therapy; Nephrotic Syndrome - etiology; Proteinuria - complications; Recombinant Proteins
• ISSN: 1931-5244; 1878-1810
• DOI: 10.1016/j.trsl.2014.06.004

The development of new and specific treatment options for kidney disease in general and glomerular diseases in specific has lagged behind other fields like heart disease and cancer. As a result, nephrologists have had to test and adapt therapeutics developed for other indications to treat glomerular diseases. One of the major factors contributing to this inertia has been the poor understanding of disease mechanisms. One way to elucidate these disease mechanisms is to study the association between the cardinal manifestations of glomerular diseases. Because many of these patients develop nephrotic syndrome, understanding the relationship of proteinuria, the primary driver in this syndrome, with hypoalbuminemia, hypercholesterolemia, hypertriglyceridemia, edema, and lipiduria could provide valuable insight. The recent unraveling of the relationship between proteinuria and hypertriglyceridemia mediated by free fatty acids, albumin, and the secreted glycoprotein angiopoietin-like 4 (Angptl4) offers a unique opportunity to develop novel therapeutics for glomerular diseases. In this review, the therapeutic potential of mutant forms of Angptl4 in reducing proteinuria and, as a consequence, alleviating the other manifestations of nephrotic syndrome is discussed.